Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 5, 2013, Pages 482-487

  Walenga, Jeanine M ^a   Prechel, Margaret ^a   Hoppensteadt, Debra ^a   Escalante, Vicki ^a   Chaudhry, Talhah ^a   Jeske, Walter P ^a   Bakhos, Mamdouh ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

anticoagulant; apixaban; heparin; heparin induced thrombocytopenia; platelets

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBON 14; ENOXAPARIN; FONDAPARINUX; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; SEROTONIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL EVALUATION; ERYTHROCYTE AGGREGATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PRIORITY JOURNAL; STANDARD; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

ANTICOAGULANT; APIXABAN; HEPARIN; HEPARIN-INDUCED THROMBOCYTOPENIA; PLATELETS;

ANTICOAGULANTS; BLOOD PLATELETS; FEMALE; HEPARIN; HUMANS; MALE; PYRAZOLES; PYRIDONES; SEROTONIN; THROMBOCYTOPENIA;

EID: 84884240480     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029613492876     Document Type: Article

References (34)

1. Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol. 2000 ; 109 (2). 336-341
2. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994 ; 71 (2). 247-251
3. Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood. 1998 ; 91 (3). 916-922
4. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost. 1995 ; 74 (3). 886-892
5. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000 ; 96 (1). 182-187
6. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000 ; 10 (suppl 1). S13 - S20
7. Walenga JM, Jeske WP, Prechel MM, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia. Semin Thromb Hemost. 2004 ; 30 (suppl 1). 57-67
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 ; 101 (5). 502-507
9. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarré R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999 ; 106 (6). 629-635
10. Bartholomew JR, Begelman SM, Almahameed A. Heparin-induced thrombocytopenia: principles for early recognition and management. Cleve Clin J Med. 2005 ; 72 (suppl 1). S31 - S36
11. Walenga JM, Koza MJ, Lewis BE, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost. 1996 ; 2 (suppl 1). S21 - S27
12. Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res. 1997 ; 88 (3). 271-281
13. Haas S, Walenga JM, Jeske WP, Fareed J. Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Hemost. 1999 ; 5 (1). 52-59
14. Linkins L, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th edition). Chest. 2012 ; 141 (suppl). e495S - e530S
15. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation.. 1999 ; 100 (6). 587-593
16. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999 ; 99 (1). 73-80
17. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 ; 103 (14). 1838-1843
18. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003 ; 163 (15). 1849-1856
19. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003 ; 108 (17). 2062-2065
20. Jeske WP, Walenga JM. Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Curr Opin Investig Drugs. 2002 ; 3 (8). 1171-1180
21. Messmore HL, Jeske W, Wehrmacher W, Walenga JM. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Saf. 2003 ; 26 (9). 625-641
22. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 ; 108 (5). 1492-1496
23. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2005 ; 11 (3). 279-287
24. Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost. 1999 ; 25 (suppl 1). 61-66
25. Walenga JM, Drenth AF, Mayuga M, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Clin Appl Thromb Hemost. 2008 ; 14 (3). 325-331
26. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT, and ecarin clotting time. Thromb Haemost. 2004 ; 91 (6). 1137-1145
27. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med. 2004 ; 164 (1). 66-70
28. Jeske WP, Jay AM, Haas S, Walenga JM. Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. Clin Appl Thromb Hemost. 1999 ; 5 (suppl 1). S56 - S62
29. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute HIT confirmed by serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011 ; 9 (12). 2389-2396
30. Goldfarb MJ, Blostein MD. Fondaparinux in acute HIT: a case series. J Thromb Haemost. 2011 ; 9 (12). 2501-2503
31. Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S, Bayer lC.. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost. 2005 ; 94 (4). 895-896
32. Greinacher A. Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost. 2011 ; 9 (12). 2386-2388
33. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost. 2012 ; 38 (5). 483-496
34. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban - an oral, direct factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol. 2008 ; 143 (1). 92-99